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Abstract
Background: Noroviruses (NoVs) are the most common cause of acute gastroenteritis (AGE) causing both sporadic
and outbreak-associated illness. Norovirus (NoV) infections occur across all ages but certain sub-groups are
considered at increased risk due to heightened transmission and/or symptom severity. Older adults are potentially
at high risk of NoV-associated illness due to frequent outbreaks in long-term care facilities (LTCFs) and severe
health outcomes following infection. Elucidation of NoV risk among older adults will support prevention,
treatment and control efforts.
Methods: We conducted a systematic literature review to summarize the published risk estimates of NoV-associated
illness, hospitalization and death among individuals aged 65 years and older. A structured search using defined NoV
and gastroenteritis (GE) terms was performed in the PubMed and EMBASE databases of human studies published
between January 1, 2003 and May 16, 2013.
Results: We identified 39 studies from high income (HI) and upper-middle income (UMI) countries. Thirty-six percent
of publications provided risk estimates based on laboratory-confirmed or epidemiologically-linked population-based
surveillance data using molecular diagnostic methods. Over the study period, estimated annual NoV rates and
extrapolated number of cases among older adults in HI and UMI countries were: 29-120/10,000 or 1.2–4.8 million
NoV-associated illnesses; 18–54/10,000 or 723,000–2.2 million NoV-associated outpatient visits; 1–19/10,000 or
40,00–763,000 NoV-associated inpatient visits; 0.04–0.32/10,000 or 2000–13,000 NoV-associated deaths. NoV was
responsible for approximately 10–20 % of GE hospitalizations and 10–15 % of all-cause GE deaths among
older adults. Older adults experienced a heightened risk of nosocomial infections. Those in LTCFs experience
frequent NoV outbreaks and the range in attack rates was 3–45 %, case hospitalization rates 0.5–6 % and
case fatality rates 0.3–1.6 %.
Conclusions: Older adults are at increased risk of severe NoV-associated health outcomes. NoV-associated
hospitalization rates were higher, more severe, resulted in longer stays and incurred greater costs than for
younger patients. NoV-associated mortality rates were approximately 200 % higher among individuals 65 years
and older compared to <5 years. The burden of NoV among older adults is expected to rise along with
societal aging and increased need for institutionalized care. NoV prevention in older adults, including
potential vaccination, may significantly impact risk of severe illness.
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Background
Noroviruses (NoVs) are non-enveloped, single-stranded
RNA viruses that cause both sporadic and epidemic ill-
ness. NoVs are the most common cause of acute
gastroenteritis (AGE) in both adults and children and
are characterized by an incubation period of 1–2 days
and acute onset of non-bloody diarrhea, nausea, vomit-
ing and abdominal cramps with possible fever, malaise
and anorexia [1–5]. NoVs are grouped into at least five
genogroups based on the viral capsid gene and within
each genogroup up to 20 genotypes have been identi-
fied [6]. Genogroups I and II are the most common in
humans with genotype GII.4 accounting for the major-
ity of norovirus (NoV) cases globally, due primarily to
GII.4 2012 Sydney and 2009 New Orleans strains in re-
cent years [2, 7–15].
NoV infections are extremely common and start to
occur early in life. In a Peruvian birth cohort approxi-
mately 80 % of NoV infections occurred within the first
year of life [16]. By adulthood, 90 % of individuals in
both England and Chile have detectable antibodies
against NoV [1]. While there is evidence of both innate
and acquired genotype-specific (but not genogroup) im-
munity, there is some controversy over the specificity
and duration of NoV immunity as well as the role of
asymptomatic infections [1, 16–20]. NoV evolution oc-
curs through adaptive changes in the capsid P2 domain,
particularly for genotype GII.4, which allows the virus to
escape herd immunity [12, 17].
NoV AGE outbreaks are extremely common due to
viral evolution, low infectious dose, extended viral shed-
ding, sustained environmental persistence, and low back-
ground immunity [6, 21–25]. NoV has distinct seasonal
activity with 75 % of all cases occurring during cooler
months and annual fluctuations in the number and
severity of cases largely due to the emergence of novel
genotypes or variants [26]. NoV is the leading cause of
foodborne illness responsible for approximately 60–65 %
of such illness in both the United States (US) and
Canada as well as being the second leading cause of
foodborne hospitalizations (26 %) following non-
typhoidal Salmonella spp (35 %) [4, 27]. While food-
borne NoV outbreaks are well documented, the most
frequent setting for outbreaks is healthcare facilities (in-
cluding both hospitals and long-term care facilities
(LTCFs)) in which person-to-person transmission of
genotype GII.4 is most common [2, 6, 28–38]. NoV
GII.4 is responsible for the majority of NoV cases in
both adults and children, however the relative importance
of specific GII.4 variants and non-GII.4 genotypes may
vary according to outbreak setting (GII.4 New Orleans
and Sydney predominate in healthcare settings) and trans-
mission route (GI.3, 6, 7 and GII.3, 6, 12 predominate in
foodborne outbreaks) [7, 8, 11]. Furthermore, in a
systematic review NoV GII.4 was reported to be associ-
ated with more severe outcomes than other genotypes in
all ages [33].
While NoV causes sporadic and outbreak AGE in all age
groups, specific sub-groups may be at heightened risk due
to increased risk of exposure and subsequent illness and/
or heightened risk of severe outcome once infected. Such
populations include the very young and old, individuals
who are immunocompromised, and those living in closed/
semi-closed communities [1, 5, 39, 40]. The pediatric
population experiences an extremely high incidence of
both non-medically attended and medically-attended
NoV illness. Recent reports indicate that, since the intro-
duction of vaccination against rotavirus disease, which has
decreased the burden of this childhood illness, NoV has
become the leading cause of pediatric AGE and hospitali-
zations in diverse settings such as the US, Finland and
Nicaragua [41–48]. There is also evidence to suggest that
older adults may be at increased risk of severe NoV illness
[49–51]. This may be due to intrinsic factors such as age-
related alterations in B and T cell function as a result of
immunosenescence or the presence of comorbidities (such
as immunosuppression, renal disease, cardiovascular dis-
ease and/or functional disability) that can reduce an indi-
vidual’s ability to mount a successful immune response to
infection and result in more severe/extended symptoms
or exacerbation of underlying conditions [49, 52, 53].
Extrinsic factors such as institutionalized housing may
further influence exposure potential or be a proxy for poor
underlying health status [33, 54–57]. Determining the
importance of NoV as a causal pathogen and estimating
the NoV-associated risk among older adults is important
for prevention efforts.
Development of vaccines against NoV is currently un-
derway, but there are no approved NoV vaccines to date
[18, 58–62]. As a frequent cause of AGE in all age
groups, prevention of NoV illness through vaccination
could have a substantial impact on the worldwide
burden of sporadic and outbreak AGE. Estimates of
the disease burden among at-risk populations, such as
older adults, will help target clinical development of
novel vaccines and inform future vaccination policy
decisions. We conducted a systematic literature review to
determine the risk of NoV-associated gastroenteritis (GE),
hospitalization and death in older adults.
Methods
Search strategy and selection criteria
We conducted a literature search within PubMed and
Embase using the following MESH (Medical Subject
Headings) terms and the free text term ‘Norwalk-like dis-
ease’: ((norovirus OR norwalk-like virus OR norwalk-like
disease) AND epidemiology) OR (gastroenteritis AND (in-
cidence OR prevalence OR surveillance OR epidemiology)
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NOT (Appendicitis OR Cholera Morbus OR Diverticulitis
OR Esophagitis OR Inflammatory Bowel Diseases OR
Mucositis OR Proctitis OR cancer OR children OR in-
fant)). We did not limit our search to studies among older
adults but reviewed all possible publications given the
scarcity of data specific to this population and the inclu-
sion of age-stratified results in community-based research.
We limited articles to human studies published in English
between January 1, 2003 and May 16, 2013, which had an
abstract available. Publications were excluded if they de-
scribed a single outbreak given that such publications,
although informative, may produce less generalizable re-
sults due to outbreak specific conditions with respect to
genotype circulation, population characteristics, outbreak
reporting and control activities. Articles were reviewed for
any information concerning NoV incidence, prevalence,
attributable proportion and attack rates among older
adults (individuals aged ≥65 years). Studies conducted
exclusively in LTCFs were considered to include predom-
inantly older adults. Other extracted information included
study setting, NoV diagnostic method, and outbreak status
(e.g., restriction of data to periods of heightened norovirus
activity or inclusion of both outbreak and non-outbreak
periods) at the time of the study. We considered
studies by duration (1 year or >1 years duration) and
availability of numerator and denominator data. We
present data according to health outcome and type of
risk estimate (incidence per 10,000 followed by attribut-
able proportion for less specific GE) for studies that clearly
identify NoV-specific estimates. Furthermore, we present
data separately for studies that exclusively reported noso-
comial cases and long-term care facility (LTCF) outbreaks.
We calculated the number of NoV GE cases in high-
income (HI) and upper-middle income (UMI) countries
for NoV outpatient visits, hospitalizations and deaths
among older adults by extrapolating estimated incidence
rates to cumulative HI and UMI country population
figures for those ≥65 years based on 2013 World Bank
population estimates (http://data.worldbank.org). HI
countries were considered to be those countries with an
annual gross national income per capita of ≥ $12,616 and
UMI countries were considered to be countries with an
annual gross national income per capita between $4086
and $12,615 per capita representing approximately 402
million individuals aged ≥65 years (209 million and 193
million in HI and UMI countries, respectively).
Results
Search results
A summary of the literature review process is given in
Fig. 1. Publications that provided information on NoV risk
by age among older adults are summarized in Table 1. We
Fig. 1 Literature search summary
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Table 1 Summary of 39 studies with norovirus (NoV) incidence or prevalence data among older adults
Author (Ref) Country Study years Study design Lab Method Risk estimation
methoda
Age Data source/population Outcome of interest
Trivedi [89] US 2009–2010 Retrospective cohort NSb C NS NORS and Medicare/LTCFsc in 3 states All cause hospitalizations and
deaths during outbreaks
Hall [51] US 1999–2007 Retrospective
regression analysis
NS C All National Center for Health Statistics/nationwide
GEd deaths
Incidence and attributable proportion
of unspecified GE deaths
Shahid [109] US 2007 Retrospective
laboratory review
Elisa B All In- and outpatient laboratory samples/city-wide
patients tested for NoV
Characteristics of NoV positive
specimens
Lopman [70] US 1996–2007 Retrospective
regression analysis
NS C All National Inpatient Sample/nationwide GE
hospital discharges
Incidence and attributable proportion
of unspecified GE discharges
Rosenthal [38] US 2003–2006 Prospective
surveillance
PCR A 18–106 y AGEeoutbreaks/LTCFs in 1 state Attack rates, case-hospitalization and
fatality rates during NoV outbreaks
Chui [71] US 1991–2004 Retrospective
database review
NS D 65– <85 y Medicare and Medicaid and US Census/
nationwide hospitalizations
Incidence of specific gastrointestinal
disease hospitalizations
Gastañaduy [45] US 2001–2009 Retrospective
regression analysis
NS C All MarketScan Insurance Claims/US emergency
and outpatient visits among insured
Incidence of emergency and
outpatient visits for cause-specified
and unspecified GE attributed to NoV
Leshem [35] US 2010–2013 Retrospective
analysis surveillance
PCR A All Sentinel community NOV surveillance (NORS
and CaliciNet)/community outbreaks in 5 states
Age-specific NoV distribution during
GII.4 outbreaks
Leshem [110] US 2010–2012 Retrospective analysis
surveillance
PCR A All Sentinel community NoV surveillance (NORS and
CaliciNet)/community outbreaks in 27 states
Age-specific NoV distribution during
GI.6 outbreaks
Hall [111] US 1979–2010 Literature review NS E All Published studies with population-based
incidence rates of NoV/US studies
Summary NoV incidence estimates
Ruzante [72] Canada 2001–2004 Retrospective
database review
NS D All Canadian Institute for Health Information, Vital
Statistics Registry, National Notifiable Diseases
database/nationwide hospitalizations and deaths
Age-specific hospitalization and
mortality incidence rates based on
NoV-specific diagnostic coding
Friesema [87] NL 2005–2007 Prospective
surveillance
PCR A 42–100 y NoV outbreaks/LTCFs with nursing wards in 6
local health services
Characteristics of NoV outbreaks by
genotype and symptoms
Van Asten [77] NL 1999–2007 Retrospective
analysis surveillance
NS C ≥65 y Statistics Netherlands (mortality), weekly
laboratory surveillance/nationwide unspecified GE
Attributable proportion of all-cause
deaths
Van Asten [68] NL 1994–2006 Retrospective
analysis surveillance
NS C ≥65 y Netherlands Information Network of GPs, NoV
surveillance, National Medical Register, Statistics
Netherland/nationwide unspecified GE
Incidence and attributable proportion
of unspecified GE deaths
Verhoef [80] NL 2009 Retrospective analysis
surveillance analysis
NS C All SENSOR study, German notifiable disease data,
other literature/nationwide
Age-specific mortality, disease burden
and burden due to foodborne
NoV GE
Spackova [82] Germany 2002–2008 Retrospective
analysis surveillance
NS A All Hospitalization reports: German notifiable disease
data/nationwide
Nosocomial GE due to enteric
pathogens including NoV
Werber [63] Germany 2004–2008 Retrospective
analysis surveillance
PCR A All German notifiable disease data, Federal Statistical
Office/nationwide
Incidence, deaths and potential life













Table 1 Summary of 39 studies with norovirus (NoV) incidence or prevalence data among older adults (Continued)
Bernard [32] Germany 2001–2009 Retrospective analysis
surveillance
PCR A All German notifiable disease data, Federal Statistical
Office/nationwide
Age-specific incidence, hospitalization
and mortality due to NoV
Gustavsson [55] Sweden 2008–2009 Retrospective
case–control
PCR B ≥60 y Hospital database/hospitalized adults at one
hospital
30 and 90 day survival rates
Fernandez [65] Spain 2000–2007 Retrospective
laboratory-based
PCR B All Patient laboratory stool samples Age-specific prevalence of enteric
pathogens in GE cases
Arias [112] Spain 2004–2005 Prospective
surveillance
PCR A All Mandatory physician reported outbreaks/
Catalonia region
Age-specific incidence of GE
Manso [67] Spain 2010–2011 Prospective
laboratory-based
PCR B All In- and outpatient laboratory stool samples/
hospital complex
Age-specific prevalence of enteric
pathogens in GE cases
Huhulescu [64] Austria 2007 Prospective cohort PCR A All Outpatients/3 physician clinics Pathogen-specific prevalence in GE
Harris [78] England/Wales 2001–2006 Retrospective
regression analysis
NS C ≥65 y Community pathogen surveillance; mortality
statistics: Health Protection Agency, Office of
National Statistics/England and Wales
Attributable proportion of GE deaths
Haustein [69] England 2000–2006 Retrospective
regression analysis
NS C ≥18 y Hospital Episode Statistics and LabBase Health
Protection Agency/nationwide
Incidence and attributable
proportion of hospital admissions
Philips [42] England 1993–1996 Prospective cohort PCR A All Outpatients/70 GP clinics nationwide Age-specific NoV incidence
Philips [113] England 1993–1996 Prospective cohort PCR A All Community and outpatient non-GE patients/
cohort and 70 GP clinics nationwide
Prevalence of asymptomatic NoV
Rovida [76] Italy 2011–2012 Retrospective
laboratory-based
PCR B All Inpatient laboratory samples (stool)/one
hospital
Pathogen-specific prevalence of GE
Kirk [83] Australia 2002–2008 Retrospective
surveillance analysis
NS A Adults GE outbreaks OzFoodNet/LTCFs nationwide Pathogen-specific GE outbreak
incidence and characteristics of GE
outbreaks
Davis [88] Australia 2004–2007 Retrospective
surveillance analysis
PCR A NS GE outbreaks OzFoodNet/LTCFs in Queensland Characteristics of NoV outbreaks in
LTCFs
Tian [66] China 2008–2009 Prospective cohort PCR B ≥14y Outpatients with AGE/GE Department one hospital NoV prevalence by age
Chan [74] Hong Kong 2012–2013 Prospective cohort PCR B All Inpatients with NoV+ AGE/one hospital NoV GII.4 distribution by age
Ho [37] Hong Kong 2001–2006 Prospective
laboratory-based
analysis
PCR A All Laboratory stool samples from inpatient, outpatients
and outbreak cases with AGE/nationwide
Characteristics of NoV outbreaks by
age, genotype and season
Tseng [114] Taiwan 2005–2007 Prospective
surveillance




Tang [75] Taiwan 2011–2012 Prospective cohort PCR B All AGE symptomatic and asymptomatic in-,
out- and emergency patients/one hospital
NoV prevalence by AGE symptom
status
Lim [15] Singapore 2004–2011 Retrospective
laboratory














Table 1 Summary of 39 studies with norovirus (NoV) incidence or prevalence data among older adults (Continued)
Al-Thani [73] Qatar 2009 Prospective cohort PCR B All AGE emergency patients/one hospital Enteric pathogen distribution by age
Greig [85] Global 1997–2007 Literature review NS E NS GE outbreaks in LTCFs/global Characteristics of enteric outbreaks
by pathogen and transmission
Utsumi [86] Global 1966–2008 Literature review NS E NS Infectious disease outbreaks in LTCFs/global Characteristics of infectious disease
outbreaks by pathogen
aMethod: A = laboratory confirmed or epidemiologically-linked population-based surveillance; B = laboratory-confirmed clinic/hospital setting; C = indirect attribution from regression modeling; D = hospital database
study select enteric illness codes without extrapolation E = literature review
bNS not specified; NS diagnostic methods may have included molecular methods; NS age often reported for LTCFs generally serving older adults















identified 39 studies conducted in 15 HI and UMI coun-
tries (44 % Europe, 28 % in the US/Canada, 23 % in
Australia, Asia and the Middle East, and 5 % global re-
views which were based predominantly in HI and UMI
countries). Data were included in the identified studies
from 1966–2013.
Risk estimates based on laboratory-confirmed or
epidemiologically-linked population-based surveillance
data were provided by 36 % (14/39) of studies, 28 %
(11/39) were hospital or clinic-based laboratory-
confirmed studies and 23 % (9/39) of the studies
indirectly attributed NoV risk based on regression
modeling. The remaining studies provided risk esti-
mates based on secondary database review of NoV-
specific hospitalization codes (5.1 %, 2/39) and literature
reviews (7.7 %, 3/39). The included literature reviews di-
verged from the current study in scope of research in-
terests and methods. NoV-associated outcomes
reported in these studies included infections, illness,
outpatient and emergency visits, hospitalizations and
deaths. Ten primary studies reported NoV incidence
data and 29 studies reported other measures of risk such
as proportion of AGE cases positive for NoV or attack
rates. Eleven publications focused predominantly on
older adults. Seven publications (5 studies and 2 re-
views) pertained exclusively to LTCFs (which did not al-
ways provide study-specific age distribution) and 1
publication pertained exclusively to nosocomial GE
cases. NoV was detected using molecular methods in 22
studies, 1 study used immunoassay, and 16 studies used
a variety of methods (which could have included mo-
lecular methods) or the method was not specified.
Thirty studies considered study periods of at least
1 year.
NoV-associated illness
No studies were identified that reported the commu-
nity age-specific incidence of non-medically-attended
NoV illness among older adults. German notifiable
disease surveillance data reported community-level
age-specific incidence of NoV-associated cases among
individuals ≥65 years, which is presumed to include
symptomatic individuals of varying severity [32, 63].
This data provided information on hundreds of thou-
sands of individuals representing both sporadic and
outbreak-associated community and institutional NoV
cases that were laboratory or epidemiologically-confirmed
[32, 63]. Age-specific mean incidence of NoV cases
(2001–2009) demonstrated a U-shaped age distribution
with the highest rates in the very young and older
adults. NoV incidence (per 10,000) estimates from
2004–8 were approximately 54 in those <5 years, 5–15
in those 5–69 years, and 48 in those ≥70 years [63]. A
second publication of the German surveillance data
(2001–2008) provided a similar age-specific pattern with
the highest incidence estimates per 10,000 in those <5 years
(43) and individuals ≥75 years (28.9-119.8 depending
on the 5-year age strata with highest estimates in
those ≥85 years) [32].
NoV-associated outpatient visits
Two studies report age-specific NoV-associated outpatient
incidence estimates that include older adults [42, 45]. Both
of these studies reported the highest rates in the very
young. Model-based rates (per 10,000) from the US were
233 among those 0–4 years, 85 among those 5–17 years,
35 among those 18–64 years, and 54 among those ≥65 years
[45]. Community-based age-specific incidence rates per
10,000 from England were 320 in those 0–4 years, 44
among 5–14 year olds, 38 among 15–44 year olds, 26
among 45–64 year olds and 37 among those ≥65 years [42].
Several publications report the mean proportion of
outpatient GE visits due to NoV among middle-older
aged adults (the lower age for many of these studies was
60 years) which ranged from 4–37 % [45, 64–67]. While
most studies did not provide confidence intervals
around these estimates, the proportion of GE outpatient
visits due to NoV among older adults was not noticeably
different from the estimated 6–26 % reported among
other age strata [45, 64–67].
While the incidence of NoV-associated outpatient
visits in older adults may not be as high as in the very
young NoV outbreaks nevertheless result in large in-
creases of unspecified GE outpatient visits in older
adults [68]. In the Netherlands, the mean monthly inci-
dence, per 10,000, of unspecified GE outpatient visits in-
creased 70–240 % above average (15.0, 17.1 and 21.7
depending on the season) during NoV outbreaks with an
overall mean of 9.1 among those ≥65 years. Taking the
mid-point in the estimated proportion of outpatient GE
visits due to NoV among older adults of 16.5 % (see
above range estimates of 4–37 %), the Dutch monthly
incidence data for unspecified GE outpatient visits can
be extrapolated ((9.1*0.165)*12)) to an overall mean an-
nual incidence per 10,000, of 18 with increased rates
during NoV outbreaks up to 43.0 among those ≥65 years.
These estimates depend substantially on the actual pro-
portion of AGE due to NoV and the level/severity of
NoV circulation. While it is expected that increased
rates would occur across all age groups, a direct com-
parison by age was not possible due to the study’s focus
on older adults.
NoV-associated emergency department (ED) visits and
hospitalizations
A single, US model-based study provided mean age-
specific incidence estimates per 10,000 for NoV-associated
ED visits which were: 38 among those <5 years, 10 among
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those 5–17 years, 12 among those 18–64 years, and 15
among those ≥65 years [45].
Four studies reported age-specific incidence rate esti-
mates for NoV-associated hospitalizations among older
adults [69–72]. Two of these studies were based on in-
direct model-derived estimates that accounted for under-
diagnosis of NoV among hospitalized patient [69, 70]
while the other two studies provided estimated NoV
hospitalization rates based on NoV-specific diagnostic
code(s) that did not include the estimated influence of
NoV on non/unspecific GE diagnoses [71, 72].
English model-derived estimates of NoV-associated
hospitalization records among adults estimated a rate
range, per 10,000, of 0.23–0.48 inpatient admissions among
18–64 year olds and 1.0–4.3 among those ≥65 years [69]
depending on the season. These estimates were based on
national GE diagnostic codes and laboratory-based patho-
gen data. Higher estimates were obtained from a US
model-based study that estimated the seasonal mean age-
specific rate per 10,000 (and range) of NoV-associated
hospitalization discharges as follows: 9.4 (5.3–18.5) among
those <5 years, 1.1 (0.6–1.9) among 5–17 year olds, 1.0
(0.5–1.4) among 18–64 year olds, 4.7 (2.9–7.7) among
65–74 year olds, 9.2 (5.0–21.5) among 75–84 year olds,
and 18.5 (10.6–37.9) among those ≥85 years [70].
Two studies reported estimated incidence rates for
NoV-specific hospitalizations based on International
Classification of Disease (ICD)-9 and 10 codes [71, 72].
While such specific estimates are considered underesti-
mates of true NoV-associated hospitalization rates, they
are useful for further burden of disease extrapolations
and provide insight into variable diagnostic practices.
One such study, a US-based Medicare and Medicaid
Services study of individuals aged 65 to 85 years (repre-
senting >90 % of US elderly) reported an annual rate,
per 10,000, of NoV-specific hospitalizations (based on
ICD-9 code 008.63) of 0.004 among 65–85 year olds
[71]. These authors highlighted that a substantial pro-
portion of non-specific GE hospitalizations are likely to
be undiagnosed viral GE in this population. Canadian-
based national hospitalization data provided higher an-
nual rates, per 10,000, of NoV-specific diagnosis (ICD-9
008.63 or ICD-10 A08.1) among middle aged and older
adults (>59 years) of 0.61 [72]. These authors further
noted that 63 % of NoV-specific hospitalizations were in
this oldest age group.
Differences in the NoV hospitalization rate estimates
between model-based indirect estimates [71, 72] and
rate estimates based on NoV-specific diagnostic codes
[69, 70], exceed 1000 fold when comparing the esti-
mates of hospitalizations above 65 years by Chui et al.
[71] to those for individuals 65–74 years reported by
Lopman et al. [70]. These large differences highlight the
extreme underestimation of risk based on pathogen-
specific diagnostic codes. The validity of the model-based
estimates is supported by seasonal peaks in non-specific
GE hospitalization diagnoses that coincide with specific
viral GE such as NoV.
The proportion of non-specific AGE ED/or hospital-
ized patients due to NoV among older adults has been
reported in several model and laboratory-based studies
[45, 69, 70, 73–76]. Qatar (laboratory-confirmed) and
US-based (model derived) studies estimated that 12 and
17 % (respectively) of GE ED visits were due to NoV among
adults aged >60 years [45, 73]. In England, >20 % of GE
emergency hospital admissions were due to NoV among
those ≥65 years during peak times of NoV activity [69].
The estimated proportion of hospitalized GE cases due to
NoV among those ≥65 years, in model-derived US and
English-based studies, was 8–13 % depending upon
whether all-cause or unspecified caused GE hospitalization
codes were included in the analyses [69, 70]. Approximately
50 % of hospitalized GE patients >65 years with stored
stool samples were NoV-positive compared to approxi-
mately <20 % among younger age groups [76]. This
higher estimate may reflect differences in the study
population due to more select sampling of sick individ-
uals with NoV-like symptoms, and may be less repre-
sentative of a broad and diverse GE population.
NoV outbreaks are associated with large increases in un-
specified GE hospitalizations in older adults. One study in
the Netherlands demonstrated an increase in the mean
monthly incidence of unspecified GE inpatient visits >30 %
above average during NoV outbreaks (2.4, 2.7 and 2.6 per
10,000 depending on the season) with an overall mean of
1.9 among those ≥65 years [68]. Taking the mid-point in
the estimated proportion of hospitalization GE visits due to
NoV among older adults of 21.5 %, the Dutch monthly inci-
dence data for unspecified GE inpatient visits can be ex-
trapolated ((1.9 *0.215)*12)) to an overall mean annual
incidence, per 10,000, of 4.9 with increased rates during
NoV outbreaks up to 7.0 [68]. These estimates are compar-
able to those estimated in a US model-based study of ap-
proximately 5–19 per 10,000 [70].
NoV-associated hospitalizations in those ≥65 years
have been reported to be more frequent, more severe,
result in longer stays and require transfer to other care
facilities following discharge compared to other age groups
[32, 70, 72]. In the US, NoV-associated hospitalization rates
and associated costs were highest among older adults, with
half of the estimated $500 million per year spent on NoV-
hospitalizations among those ≥65 years [70].
NoV-associated mortality
Older adults contribute the vast majority of NoV-
associated deaths [51, 55, 63]. US and German-based
NoV-associated mortality rate estimates demonstrate a
sharp increase with age [51, 63]. Specifically, US-based
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average annual mortality rate estimates, per 10,000, were
0.013 in those <5 years, 0.002 among those 5–64 years,
and 0.20 among those ≥65 years (with fluctuations up to
55 % in this age group during non-epidemic and epi-
demic years) [51]. German NoV surveillance data re-
ported similar NoV-associated mortality rate estimates
per 10,000 namely, <0.01 in those <70 years to approxi-
mately 0.32 among those ≥70 years [63].
Dutch model-based estimates suggest that seasonal vi-
ruses account for nearly 5 % of all-cause mortality in the
elderly with influenza accounting for the most deaths
(approximately 2 %), followed by respiratory syncytial
virus (1.5 %), parainfluenza (1 %) and NoV (0.2 %). The
percentage of all deaths due to NoV increased with age
to 0.5 % among those ≥85 years [77].
In the US, approximately half of all GE deaths (re-
gardless of age) are coded as ‘cause unspecified’ of
which older adults account for an estimated 83 %
[51]. Among this population, Clostridium difficile is
considered the leading cause of all-cause GE deaths
and in the US NoV is the second leading cause (8 %)
of all-cause GE deaths [51, 78, 79]. In analyses that
excluded deaths due to C. difficile, NoV contributed
16 % of GE deaths among older adults [51]. These
findings are comparable to data from England and
Wales that modeled seasonal variations in death ac-
cording to seasonal variations in laboratory reports
(excluding deaths due to Clostridium difficile) where
NoV accounted for 20 % of older adult deaths due to
infectious intestinal disease and 13 % of deaths regis-
tered as ‘non-infectious gastrointestinal disease’ [78].
Data from the Netherlands estimated that 14 % of un-
specified GE deaths were attributable to NoV among
older adults with outbreak-associated increases of ap-
proximately 130 % above the mean monthly unspecified
GE death incidence per 10,000 (>0.06 compared with
0.026) [68]. Based on an attributable proportion of 14 %,
this equates to a mean annual NoV incidence per
10,000 of 0.04 with increases to >0.10 during outbreaks.
While these mean estimates are lower than the esti-
mated rates per 10,000 based on German (0.32) and US
(0.20) data, the estimated rates during outbreaks reached
a comparable level [51, 63, 68].
One publication extrapolated German surveillance data
to the Dutch population to obtain estimated mean age-
specific NoV case fatality rate per 1000 (95 % CI) of: 0.09
(0.01–0.27) for those <1 year, 0.00 (0–1.12) for those 1–
4 years, 0.00 (0–0.04) for those 5–11 years, 0.09 (0–0.34)
for those 12–17 years, 0.03 (0.01–0.06) for those 18–
64 years and 0.63 (0.55–0.73) for those ≥65 years [80].
In a Swedish-based study of hospitalized adults with
community-onset NoV infection, nearly 8 % of individ-
uals died within 30 days of a NoV-positive sample (e.g.,
an 8 % 30-day NoV mortality rate) and all deaths
occurred among those ≥60 years [55]. Individuals with
underlying medical conditions had a higher 30-day mor-
tality rate than those without such conditions (10.5 %
compared to 5.3 %). The study authors did not specify
the relevant underlying conditions. However, another
study by Harris et al., noted that circulatory, respiratory
and neoplastic conditions were important contributors
to NoV-associated deaths [78].
Institutional NoV outbreaks
National surveillance data from HI countries have re-
ported that the majority of NoV outbreaks occur in hos-
pitals and LTCFs [31, 32, 35]. NoV GII.4 has been
identified in a majority of institutional outbreaks among
older adults [32, 35].
Nosocomial NoV
NoV outbreaks frequently occur in hospitals and at-
tack rates can be extremely high (up to 60 % of pa-
tients and 40 % of staff ) [31, 32, 39, 81]. In a study
of nearly 40,000 NoV cases captured within the German
surveillance system, age ≥70 years was significantly associ-
ated with nosocomial (e.g., NoV onset >2 days after hos-
pital admission) NoV infection (risk ratio [RR] = 14.3,
95 % CI 13.5–15.0 for individuals 70–81 years and RR =
13.0, 95 % CI 12.4–13.6 for individuals >81 years com-
pared to those ≤25 years) [82]. The proportion of NoV
cases considered to be nosocomial showed a U-shaped
curve with the largest proportions in those ≥70 years
(65 %) followed by infants <1 year (16 %). Approximately
66 % of all NoV nosocomial infections occurred in elderly
adults and the importance of nosocomial infections
among this population was more pronounced for NoV
than for other routinely surveyed GE pathogens such as
rotavirus, Salmonella and Campylobacter. German sur-
veillance data indicate that 83 % of NoV hospitalized cases
among those >74 years originated from institutional set-
tings such as hospitals or LTCFs [32].
NoV outbreaks in LTCFs
LTCFs are a common setting for AGE outbreaks (50 % of
all AGE outbreaks occurred in LTCFs as reported in a na-
tionwide Australian study) of which 30-80 % were due to
NoV, largely driven by NoV GII.4 [15, 31, 35, 38, 83–87].
Within the US and Australia, the annual number of
NoV outbreaks was estimated to be 6–8 per 100
LTCFs [38, 83].
Seven studies were identified that pertained exclusively
to LTCFs [38, 83, 85–89]. The definition of LTCF, facility
characteristics, and resident population differed between
studies, however LTCF generally referred to facilities that
provided prolonged care for individuals who required
daily living and/or nursing care support. None of the 7
identified studies provided the age distribution for the
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study population and only one [89] provided age-
stratified results. NoV outbreaks in LTCF settings were
characterized by high levels of person-to-person trans-
mission (in many reports >90 % of such outbreaks were
transmitted person-to-person) facilitated through care-
giving, close contact between residents and staff, as well
as frequent movement of infected individuals within and
between facilities [31, 38, 83, 85]. NoV outbreaks in
LTCFs were associated with higher attack rates and
deaths than other causes of AGE outbreaks [31, 38, 63,
83, 88, 89]. NoV was responsible for 70 % of all viral and
bacterial enteric illnesses, 58 % of all hospitalizations,
and 27 % of deaths in a review of enteric illness out-
breaks in LTCFs [85]. This represents a much higher im-
pact on severe health outcomes among LTCFs compared
to other settings (versus 8–17 % of AGE hospitalizations
and 8–20 % of GE deaths due to NoV in non-LTCF
settings) [45, 51, 68–70, 73, 78].
Table 2 summarizes the attack, case hospitalization
and case fatality rates reported for NoV in the identi-
fied LTCF studies. Attack rates ranged from 3 to 45 %
depending on the study and largely reflected differ-
ences in the number reporting/laboratory confirm-
ation and definition of individual outbreaks, facility
characteristics, and study population [38, 83, 85–88].
The median attack rate estimates from a global review
by Utsumi et al. [86] for residents (45 %) and staff
(42 %) included outbreaks with attack rates of 100 %
which may overestimate ‘typical’ attack rates. However,
these high estimates are similar to GII.4 attack rates
among individual wards of nursing homes estimated
from the Netherlands [87].
Case hospitalization rates ranged from 0.5 % [87] to
6 % [86]. The highest median hospitalization rates were
reported again in the review by Utsumi et al. which may
reflect reporting differences in the primary studies [86].
However, data from a US-based study and a second glo-
bal review suggest case hospitalization rates range be-
tween 2–4 % depending on the sub-population within
LTCFs [38, 85]. Considered from a different perspective,
of all enteric outbreaks in LTCFs, NoV is responsible for
58 % of hospitalizations [85]. An estimated 34.4 NoV-
associated hospitalizations occur annually per 10,000
individuals in LTCFs [88].
Case fatality rates due to NoV in residents of LTCFs
ranged from 0.3 % [83] to 1.6 % [87]. The variability in
case fatality rate is presumably due to study-specific def-
initions of NoV-associated deaths, which included broad
all-cause mortality during outbreaks in highest estimates
obtained in the Netherlands [87].
Table 2 Attack, case hospitalization and case fatality rates during norovirus -associated outbreaks in long-term care facilities


















1136 Residents and staff – – 0.3
Rosenthal [38]b Oregon, US 163 Residents 4; All facilities 3.1; All facilities 0.5; All facilities
6; Nursing facilities 1.8; Nursing facilities 0.5; Nursing facilities
3; Non-nursing facilities 4.3; Non-nursing facilities 0.4; Non-nursing facilities
Friesma [87]c 5–6 local health
services, NL







Greig [85] Global review 43 Residents – 4.2 0.7
Utsumi [86]d Global review 23 Residents 45 Residents 6 –
Staff 42 Staff
aDefinition of Nov-associated outcome may have differed across individual studies
bRosenthal et al. [38] defined nursing facility as those institutions providing 24-h nursing care and non-nursing facility otherwise; average attack rates reported
cFriesma et al. [87] report NoV outbreaks in both residents and staff but results reported for residents only; median attack rates reported
dUtsumi et al. [86] report median attack rates
Lindsay et al. BMC Infectious Diseases  (2015) 15:425 Page 10 of 16
Trivedi et al. [89] modeled the rates of all-cause
hospitalization and mortality during NoV outbreaks com-
pared to non-outbreak periods among LTCF residents (for
facilities with ≥1 reported outbreak) within 3 US states.
All-cause hospitalization (adjusted RR [aRR] = 1.09; 95 %
CI 1.05–1.14) and mortality (aRR = 1.11; 95 % CI 1.05–
1.18) rates were significantly increased during NoV out-
break periods. Increased rates were particularly apparent
among residents ≥ 90 years (aRR = 1.24; 95 % CI 1.13, 1.37
for all-cause hospitalizations and aRR = 1.28; 95 % CI 1.14,
1.42 for all-cause mortality). The estimated 12 % in-
crease in all-cause hospitalizations and 25 % increase
in deaths occurred primarily during the first 2 weeks
of outbreaks, with estimates of 1 excess hospitalization
for every 4 outbreaks and 1 excess death for every 9
outbreaks.
A few key factors were found to influence NoV risk
and/or severity in the LTCF setting which include NoV
genotype, age, comorbidity and facility characteristics.
NoV GII.4 outbreaks in LTCFs have been associated
with more frequent, severe and longer duration of illness
compared to non-GII.4 outbreaks [38, 87]. The mean
age of NoV cases in LTCFs has been reported to be in
the mid-80s, and severe outcomes (including all-cause
hospitalizations and mortality) were most frequently re-
ported in the very aged [38, 87, 89]. Facility characteris-
tics, such as level and adequacy ratings of nursing
support within LTCFs were associated with the variable
risk and severity of NoV outbreaks suggesting that poor
underlying health status of residents may influence NoV
susceptibility and transmission and inadequate nursing
care is an important determinant of NoV-associated
mortality [38, 89].
Estimated number of NoV cases in HI and UMI settings
According to 2013 World Bank estimates, there were ap-
proximately 209 million individuals ≥65 years living in
HI countries (16 % of total HI population) and 193 mil-
lion individuals ≥65 years living in UMI countries (8 %
of total UMI population).
Figure 2 provides estimated rates of NoV-associated
health outcomes among older adults and extrapolated an-
nual cases in HI and UMI countries. The wide range of the
estimates reflect the differences in 1) study population; 2)
detection and attribution methodology of NoV to GE epi-





Fig. 2 Estimated annual incidence rate per 10,000 (extrapolated number) of norovirus-associated gastroenteritis cases in older adults living in high
and upper-middle income countriesa. aPopulation based on 2013 World Bank estimate of 401,680,000 individuals aged ≥65 years in high
(208,960,000) and upper-middle income (192,720,000) countries. bAnnual mortality rate estimates based on following sources: Hall et al.
[51], Werber et al. [63], van Asten et al. [68]. cAnnual inpatient rate estimates based on following sources: Haustein et al. [69], Lopman
et al. [70], van Asten et al. [68]. dAnnual outpatient rate estimates based on following sources: Gastanaduy et al. [45], Phillips et al. [42],
van Asten et al. [68]. eAnnual case rate estimates based on following sources: Werber et al. [63], Bernard et al. [32]; if estimate accounts
for incidence data published in de Wit et al. [94] which was published prior to the inclusion dates for this review, the upper incidence
rate estimate would be 310 per 10,000 which corresponds to 12,452,080 estimated cases in high and upper middle income countries annually
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Discussion
We identified 39 studies from HI and UMI countries
that reported information on sporadic and outbreak-as-
sociated NoV risk among older adults. Our findings dem-
onstrate a high burden of NoV-associated illness in all
ages with the highest burden of severe NoV-associated
outcomes occurring among older adults. The inci-
dence of NoV-associated hospitalization in older
adults was more frequent, more severe, resulted in
longer stays and incurred greater costs than for youn-
ger patients [32, 68–70, 72]. Older adults are a key
driver of overall NoV-hospitalization rates reported
across different settings [8, 33, 82, 90]. Estimated
NoV-associated mortality rates were roughly 200 %
higher among those ≥65 years compared to <5 year olds.
In older adults, NoVs cause approximately 10–20 % of GE
hospitalizations, 10–15 % of GE deaths, and ≥0.2 % of all-
cause mortality [45, 51, 68, 69, 73, 77–79]. While our re-
view was limited to English-language publications thereby
potentially missing relevant manuscripts published in
other languages, our review highlights the substantial risk
of NoV among institutionalized older adults in HI and
UMI countries and supports the adverse impact NoV-
associated illness has on healthcare costs and institutional
control efforts including a substantial disruption in LTCF
staff time and cost (including staff illness) as a result of
NoV outbreaks [31, 38, 70, 83–89, 91–93].
We did not identify any community-based incidence
data for non-medically attended NoV-associated illness in
older adults. Previously published data (2001), however,
provide age-specific GE incidence rates (non-pathogen
specific) in the general population per 10,000 of: 7400
among those <1 year, 9000 among those 1–4 years, 4810
among those 5–11 years, 1570 among those 12–17 years,
2340 among those 18–64 years and 1940 among ≥65 year
olds [94]. The estimated percentage of GE cases positive
for Norwalk-like virus or Sapporo-like virus was 16 %
(across all ages but within the range of 4–37 % detected in
elderly outpatient visits). Thus, it can be roughly estimated
that older adults experienced an incidence of 310/10,000
(1940 *0.16) of community-based NoV-associated illnesses
representing an approximate percentage increase of 400
to 700 % from the estimated rate of NoV-associated out-
patient visits (37–54/10,000) among older adults. While a
direct comparison of NoV rates between age groups was
not the aim of this review, data suggests that non-
medically attended NoV illness and outpatient rates are
lower for older adults compared to children <5 years.
We found heightened NoV-associated hospitalizations
and deaths among older adults with underlying health
conditions which is in agreement with a recent review
by Trivedi et al. [95] that identified immunosuppressive
conditions to be common among NoV-associated deaths
in older adults. The immediate cause of death reported
among these individuals included aspiration/pneumonia,
sepsis, gastrointestinal and cardiac complications. There
is, however, limited reporting of susceptibility to, and
clinical course of, NoV among older adults according to
underlying health status. Data is also limited on the im-
pact of NoV-associated AGE on daily living, function
and quality of life among this population.
The ability to compare or pool study estimates in our
review was limited by the variability inherent in the data
which reflects different study designs and study popula-
tions, inaccuracies in NoV detection/attribution and po-
tentially marked differences in NoV activity over different
time periods. Among the publications included in our re-
view, factors of interest were often omitted such as: age
distribution, living situation (community or LTCF), health
status and/or contributing factors, NoV circulation and
genotype, and definition of AGE or GE. Moreover, while
much data described AGE outbreaks in healthcare set-
tings, endemic (e.g., cases identified outside of a recog-
nized outbreak setting) rates of NoV illness tended to
be less well described. It was difficult to differentiate
sporadic (endemic) and outbreak-related NoV risk esti-
mates in studies that reported variable levels of NoV
circulation, such as surveillance data or secondary
healthcare utilization databases. However it is clear that
NoV-associated illnesses and severe outcomes peak
during periods of high viral circulation and that NoV
outbreaks significantly increase GE and all-cause hospi-
talizations and mortality among older adults.
One specific source of bias that is well recognized for
common non-specific infectious illnesses, is the impact
of both under-ascertainment (of illnesses that do not re-
sult in a healthcare visit) and under-reporting (correctly
diagnosing and reporting NoV cases with non-specific
symptoms) [96]. While age-specific (and, ideally, health
outcome-specific) NoV multiplication factors are not
routinely used, the underestimation of NoV-risk for all
ages, including older adults, can be substantial. This is
evident by 1) the estimated 400–700 % increase in the
NoV incidence rate of community-level illness [94] com-
pared to the estimated rate of NoV-associated outpatient
visits among the elderly [42] and, 2) the estimated ≥1000
fold difference in NoV hospitalization rate estimates
based on NoV-specific diagnostic codes [71, 72] and
model-based indirect estimates that account for undiag-
nosed NoV cases [69, 70]. Among older adults NoV
GII.4 is the most predominant genotype in outbreak, in-
patient, LTCFs and community settings, potentially due
to a combination of novel GII.4 mutations that emerge
(such as the insertion of an amino acid in recent GII.4
strains) and limited immune response among older
adults due to immunosenescence [35, 38, 66, 90, 97].
NoV GII.4 has also been identified as the dominant
genotype causing illness in children with slightly greater
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genotype variability (particularly in the GII genogroup)
due, perhaps, to less dynamic evolution of non-GII.4 ge-
notypes [8, 11, 90, 97]. Interpretation of NoV risk and
genotype distribution across settings is contingent not
only upon ascertainment and reporting of individual cases
but also upon systematic capture of viral circulation and
illness through established surveillance systems. NoV sur-
veillance is largely designed to identify and control out-
breaks, and notifiable disease reporting may differentially
capture and diagnostically confirm symptomatic infections
in closed/semi-closed settings rather than open settings,
thereby providing risk estimates and genotype informa-
tion specific to such settings. NoV-associated illness,
hospitalizations and deaths among older adults outside
of institutional settings may be missed, resulting in an
underestimate of risk and less-than-complete under-
standing of genotype distribution. Given that older
adults seek healthcare for GE less frequently than the
very young [98], it may be even more likely that spor-
adic NoV-associated illness in community-living older
adults is underestimated.
Globally, we are experiencing a rapid increase in
the relative proportion of older adults due to smaller
family size (i.e., fewer children) and longer life expect-
ancy. It is estimated that the proportion of individuals
>60 years will double between 2010 and 2050 reach-
ing an estimated 20–30 % in many Organisation for
Economic Co-operation and Development (OECD)
countries and even 38–40 % in countries such as
Japan and Korea [99]. This trend is also projected for
the very aged (>80 years) with concomitant increases
in the need for long term care (expected to quadruple
by 2050 from an estimated 0.2–2 % of total OECD
population to 0.8–8 % of total OECD countries popu-
lation). Preparations are needed for the impact of the
‘age wave’ on the burden of disease caused by com-
mon infectious diseases such as NoV [99–101]. Thus,
the burden of NoV illness in older adults is likely to
increase as the number and proportion of aged, and
the very aged (>80 years), increases. While we have
provided rough estimates of the absolute number of
NoV-associated GE cases in older adults living in HI
and UMI countries based on extrapolated annual inci-
dence rates, these figures should be interpreted with
caution as the estimates do not account for factors
such as country-specific age structure, health status
or institutional residence status among older adults.
Several virus-like particles (VLP) NoV vaccines are
in development which target key genotypes using a
variety of production methods and administration
routes [102]. Recent Phase 2 study results of a bivalent
(GI and GII.4) VLP NoV vaccine have demonstrated
that a candidate vaccine was generally well tolerated
with efficacy observed against symptomatic illness
among human volunteers vaccinated and subsequently
challenged with live NoV [102, 103]. Given the increased
risk of NoV-associated hospitalizations and death among
older adults, regulatory approval of a safe and effective
NoV vaccine which has broad coverage for common
and emerging genotypes, that provides durable im-
munity and is efficacious among older adults, could
have a positive impact in this population [104]. NoV
vaccination may be a particularly attractive prevention
tool for institutionalized older adults, and staff who
have contact with them, for whom current control ac-
tivities have shown limited/variable impact on out-
break duration and attack rates [78, 105]. This has
been the case for influenza in which, like NoV, older
adults account for approximately 90 % of deaths and 50 %
of hospitalizations. Influenza vaccination has resulted in
a 77 % reduction in influenza-associated hospitalizations
in adults aged ≥50 years [51, 55, 63, 70, 106, 107]. While
NoV-associated age-specific mortality and hospitalization
rates among the elderly are generally lower than those re-
ported for influenza, NoV estimates can reach a compar-
able level among the very aged during epidemic NoV
seasons (such as 2006/7) [70, 108].
Conclusion
We described the NoV-associated burden of disease among
older adults and highlighted the importance of severe NoV-
associated outcomes in this population. We estimated that
in HI and UMI countries there are 1.2 to 4.8 million NoV-
associated illnesses (accounting for under-ascertainment
this estimate could increase to 12.5 million), 723,000 to 2.2
million NoV-associated outpatient visits, 40,000 to 763,000
NoV-associated hospitalizations, and 2000 to 13,000 NoV-
associated deaths annually. Older adults living in LTCFs are
at increased risk of NoV-associated illness due to frequent
outbreaks and severe health outcomes. NoV prevention has
the potential to significantly reduce the NoV-associated
burden of disease in all ages with perhaps the most impact
on severe outcomes in older adults. This potential impact
will be heightened in the coming years due to rapid aging
of societies and projected increases in aged individuals re-
quiring long term care.
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